{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:42Z","timestamp":1787242662745,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10384-025-01239-7","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T01:20:39Z","timestamp":1750900839000},"page":"926-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of intraocular pressure elevation following intravitreal injection of 70 \u00b5l aflibercept 8 mg"],"prefix":"10.1007","volume":"69","author":[{"given":"Xien","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8795-6536","authenticated-orcid":false,"given":"Keiko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"1239_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"1239_CR2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"1239_CR3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser P, Nguyen Q, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1239_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"1239_CR5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1239_CR6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","volume":"6","author":"M Singer","year":"2022","unstructured":"Singer M, Albini TA, Seres A, Baumal CR, Parikh S, Gale R, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2022;6:97\u2013108.","journal-title":"Ophthalmol Retina"},{"key":"1239_CR7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2023;37:6\u201316.","journal-title":"Eye"},{"key":"1239_CR8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration 2-year results of the trex-amd study. Ophthalmol Retina. 2017;1:314\u201321.","journal-title":"Ophthalmol Retina."},{"key":"1239_CR9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1239_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10384-020-00783-8","volume":"65","author":"Y Tsunekawa","year":"2021","unstructured":"Tsunekawa Y, Kataoka K, Asai K, Ito Y, Terasaki H. Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. Jpn J Ophthalmol. 2021;65:69\u201376.","journal-title":"Jpn J Ophthalmol"},{"key":"1239_CR11","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00417-024-06519-5","volume":"262","author":"H Ota","year":"2024","unstructured":"Ota H, Kataoka K, Asai K, Takeuchi J, Nakano Y, Nakamura K, et al. Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naive age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:3483\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1239_CR12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3129\/i07-172","volume":"42","author":"H Hollands","year":"2007","unstructured":"Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42:807\u201311.","journal-title":"Can J Ophthalmol"},{"key":"1239_CR13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/archophthalmol.2010.297","volume":"128","author":"MP Frenkel","year":"2010","unstructured":"Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128:1523\u20137.","journal-title":"Arch Ophthalmol"},{"key":"1239_CR14","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ajo.2007.01.052","volume":"143","author":"RE Frenkel","year":"2007","unstructured":"Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034\u20135.","journal-title":"Am J Ophthalmol"},{"issue":"930\u20134","key":"1239_CR15","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(930\u20134): e1.","journal-title":"Am J Ophthalmol"},{"key":"1239_CR16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","volume":"18","author":"M Gismondi","year":"2009","unstructured":"Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18:658\u201361.","journal-title":"J Glaucoma"},{"key":"1239_CR17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"1239_CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201cTreat-and-Extend\u201d regimen. Ophthalmol Retina. 2019;3:393\u20139.","journal-title":"Ophthalmol Retina."},{"key":"1239_CR19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","volume":"95","author":"TJ Good","year":"2011","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111\u20134.","journal-title":"Br J Ophthalmol"},{"key":"1239_CR20","doi-asserted-by":"crossref","first-page":"12246","DOI":"10.1038\/s41598-021-91832-w","volume":"11","author":"M Maruyama-Inoue","year":"2021","unstructured":"Maruyama-Inoue M, Inoue T, Mohamed S, Kitajima Y, Ikeda S, Ito A, et al. Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration. Sci Rep. 2021;11:12246.","journal-title":"Sci Rep"},{"key":"1239_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-2415-12-53","volume":"12","author":"JM Kim","year":"2012","unstructured":"Kim JM, Park KH, Han SY, Kim KS, Kim DM, Kim TW, et al. Changes in intraocular pressure after pharmacologic pupil dilation. BMC Ophthalmol. 2012;12:53.","journal-title":"BMC Ophthalmol"},{"key":"1239_CR22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.survophthal.2009.05.001","volume":"54","author":"MB Sultan","year":"2009","unstructured":"Sultan MB, Mansberger SL, Lee PP. Understanding the importance of IOP variables in glaucoma: a systematic review. Surv Ophthalmol. 2009;54:643\u201362.","journal-title":"Surv Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01239-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01239-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01239-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:21:33Z","timestamp":1762881693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01239-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01239-7","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"X. Lu, None; K. Kataoka, Grants (Chugai), Honoraria for lectures (Bayer, Chugai, Santen, Novartis, Senju, Boehringer Ingelheim, Canon, ZEISS), Advisory Board (Chugai), Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid (Vision Academy supported by Bayer) ; M. Kumagai, None; Y. Nochi, None; A. Yamamoto, Honoraria for lectures (Novartis, Bayer, Chugai); R. Ko, None; A. A. Okada, Grants (Alcon), Consulting fees (Apellis, Allergan, Astellas, Biocon Biologics, Daiichi-Sankyo, Kowa, Bayer), Honoraria for lectures (Bayer, Chugai, Mitsubishi Tanabe, Otsuka, Pfizer, Santen, Senju, Novartis).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}